₹663.80, up 4.2% from previous close, while the benchmark Sensex was up 1.1% at 35,104.71.In a notification to the exchanges, Cipla on Sunday announced the launch of its generic version of remdesivir.
It is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed covid-19.In May, Gilead Sciences Inc, developer of remdesivir, had extended a voluntary non-exclusive license to Cipla to manufacture and market the latter's generic version of the drug.Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent.